The fundamental barriers to access to medicine remain when they don’t need to
Eighteen years after the Durban conference, government efforts to increase medicine access – beyond HIV treatments – have been excruciatingly slow. Though ARVs are now widely available, many more shocking cases of injustice in access to essential medicines remain. It should not be so. We can change it, now.
Daily Maverick | 24th October, 2018
Pharma is getting away with lots of patent ‘evergreening’ in India
After a controversial court case five years ago in India, drug makers were put on notice that additional patents on medicines would have to demonstrate a degree of innovation. But a new analysis finds the vast majority of so-called secondary patents were granted for only marginal improvements, raising questions about the extent to which companies are adding value to their drugs.
STAT+ | 23rd October, 2018
Research Group Identifies Over-Patenting Of Pharmaceuticals In India, Calls For Patent Reform
The tricontinental research group “accessibsa” has found that while the Indian Patent Office rejects 40 percent of pharmaceutical patent applications, it should be rejecting 90 percent of applications to comply with Indian patent law, according to the results of its recent study of Indian patent data.
Intellectual Property Watch | 17th October, 2018
Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Undue Monopolies
The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court.
Intellectual Property Watch | 13 September, 2018
SECTION27, TAC launch new treatment access history
On the 26th of July at the International AIDS conference, hosted in the Netherlands, SECTION27 and the Treatment action campaign (TAC) launched a new publication documenting the history of the access to medicines movement in South Africa.